Qatar Pharmaceuticals & Healthcare Report

Providing expert analysis, independent forecasts and competitive intelligence on the pharmaceuticals and healthcare industry.

Report includes: BMI Industry View, Industry SWOT Analysis, Industry Forecasts, BMI's Pharmaceuticals and Healthcare Risk Reward Index, Market Summary, Economic Forecasts, Company Profiles and Competitive Landscape.

Why you should buy this report

  • Benefit from the latest market opportunities
  • Understand the threats to your operations and investments and protect your company against future risks
  • Gain insight on emerging trends that could support, strengthen or disrupt your activities in the market
  • Get a full view of the competitive landscape to assess your market position
×

Sign up to download the Qatar Pharmaceuticals & Healthcare Report

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.

Thank you for your interest

You will shortly receive your free executive summary by email.

Qatar Pharmaceuticals & Healthcare Report
Product Price
$1,295.00

BMI View: We remain positive in our outlook for Qatar's pharmaceutical and healthcare markets, in spite of lower oil prices. Government commitment to maintaining quality healthcare provision and the roll-out of health insurance will both drive expenditure growth.

Headline Expenditure Projections

  • Pharmaceuticals: QAR1.79bn (USD491mn) in 2014 to QAR2.00bn (USD548mn) in 2015; +11.5% in local currency and US dollar terms. Forecast unchang ed from Q 4 15.

  • Healthcare: QAR17.25bn (USD4.74bn) in 2014 to QAR18.86bn (USD5.18bn) in 2015; +9.3% in both local currency and US dollar terms. Forecast in line with Q 4 15 .

Risk/Reward Index

Qatar's risks are particularly low in comparison with the rest of the Middle East and Africa (MEA) region, although its potential rewards are dampened by the small market size. Nevertheless, Qatar's high level of urbanisation, rapid population growth and rising prevalence of chronic lifestyle diseases create an environment in which there is strong potential for market growth. In BMI's Pharmaceutical Risk/Reward Index for the MEA region in Q116, Qatar has retained its position of fourth place, with the country's score remaining at 55.5 out of 100.

Key Trends and Developments

  • Qatar Airways Cargo introduced two new dedicated pharmaceutical routes from India to Doha, as the firm looks to capitalise on industry growth in the Middle East. The first new 'Pharma Express' route began in November 2015. To date, the company is the only airline offering this dedicated service to the pharmaceutical industry, according to Qatar Airways Chief Officer Cargo Ulrich Ogiermann.

  • According to Minister of Public Health Abdullah bin Khalid Al Qahtani in October 2015, about QAR1.29bn (USD354.3mn) was spent on the treatment of Qatari citizens under the social health insurance system between July 2013 to October 21 2015.

  • In October 2015, Qatar Pharma announced its plans to set up a new pharmaceutical production line for insulin and anti-cancer drugs in the country. The plant would be first of its kind in the Gulf Cooperation Council (GCC).

BMI Economic View

Qatar has so far largely defied the slump in global energy prices, and will continue to record stronger economic growth than the rest of the region over the coming years. While modest headwinds are rising as the government adopts a more conservative fiscal stance, both infrastructure growth and the expansion of the services economy will remain buoyant.

BMI Political View

Qatar's decision to send 1,000 ground troops to Yemen - nearly 10% of its armed forces - marks a decisive milestone in the country's foreign policy. The move aligns Qatar more closely with its Gulf neighbours, but means that the country risks becoming bogged down in a drawn-out conflict to little obvious benefit. Any Qatari casualties could provoke discontent among the small native population.

BMI Industry View
7
SWOT
9
Political
11
Economic
12
Operational Risk
13
Industry Forecast
15
Pharmaceutical Market Forecast
15
Table: Pharmaceutical Sales, Historical Data And Forecasts (Qatar 2011-2019)
16
Healthcare Market Forecast
17
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Qatar 2011-2019)
19
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Qatar 2011-2019)
19
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Qatar 2011-2019)
19
Prescription Drug Market Forecast
20
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Qatar 2011-2019)
21
Patented Drug Market Forecast
22
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Qatar 2011-2019)
23
Generic Drug Market Forecast
24
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Qatar 2011-2019)
25
OTC Market Forecast
26
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Qatar 2011-2019)
27
Pharmaceutical Trade Forecast
28
Table: Pharmaceutical Trade Data And Forecasts (Qatar 2013-2019)
29
Table: Pharmaceutical Trade Data And Forecasts local currency (Qatar 2013-2019)
30
Key Risks To BMI's Forecast Scenario
31
Macroeconomic Forecasts
34
Table: BMI And Bloomberg Consensus Forecasts - Brent
35
Expenditure Breakdown
37
Industry Risk Reward Indices
42
Middle East and Africa Risk/Reward Index
42
Qatar Risk/Reward Index
49
Rewards
49
Risks
49
Market Overview
51
Industry Trends And Developments
52
Epidemiology
52
Healthcare Sector
57
Healthcare Sector Developments
58
GCC Unified Drug Pricing
61
Table: Healthcare Resources (Qatar 2009-2014)
62
Table: Healthcare Personnel (Qatar 2009-2014)
62
Table: Healthcare Activity (Qatar 2009-2014)
63
Health Insurance
63
Healthcare IT
66
Research & Development
67
Clinical Trials
69
Regulatory Development
70
Regional Regulatory Developments
71
Intellectual Property Regime
74
Pricing And Reimbursement Regime
74
Competitive Landscape
77
Pharmaceutical Industry
77
Pharmaceutical Wholesale And Retail
79
Company Profile
80
Ebn Sina Medical
80
GlaxoSmithKline
82
Medicare Group
84
Merck & Co
86
Novartis
88
Pfizer
90
Qatar Pharma
92
Demographic Forecast
94
Demographic Outlook
94
Table: Population Headline Indicators (Qatar 1990-2025)
95
Table: Key Population Ratios (Qatar 1990-2025)
95
Table: Urban/Rural Population & Life Expectancy (Qatar 1990-2025)
96
Table: Population By Age Group (Qatar 1990-2025)
96
Table: Population By Age Group % (Qatar 1990-2025)
97
Glossary
99
Methodology
101
Pharmaceutical Expenditure Forecast Model
101
Healthcare Expenditure Forecast Model
101
Notes On Methodology
102
Risk/Reward Index Methodology
103
Index Overview
104
Table: Pharmaceutical Risk/Reward Index Indicators
104
Indicator Weightings
105

The Qatar Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Qatar Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Qatar pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's pharmaceutical and healthcare market forecasts for Qatar, to test other views - a key input for successful budgeting and strategic business planning in the Qatari pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Qatari pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Qatar.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.